- Home
- MYNZ vs SNOA Comparison
MYNZ vs SNOA Comparison
Compare MYNZ & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- SNOA
- Stock Information
- Founded
- MYNZ 2021
- SNOA 1999
- Country
- MYNZ Germany
- SNOA United States
- Employees
- MYNZ N/A
- SNOA N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- SNOA Health Care
- Exchange
- MYNZ Nasdaq
- SNOA Nasdaq
- Market Cap
- MYNZ 5.5M
- SNOA 6.4M
- IPO Year
- MYNZ 2021
- SNOA 2007
- Fundamental
- Price
- MYNZ $1.44
- SNOA $2.97
- Analyst Decision
- MYNZ Buy
- SNOA
- Analyst Count
- MYNZ 2
- SNOA 0
- Target Price
- MYNZ $14.00
- SNOA N/A
- AVG Volume (30 Days)
- MYNZ 117.3K
- SNOA 23.3K
- Earning Date
- MYNZ 07-15-2025
- SNOA 08-07-2025
- Dividend Yield
- MYNZ N/A
- SNOA N/A
- EPS Growth
- MYNZ N/A
- SNOA N/A
- EPS
- MYNZ N/A
- SNOA N/A
- Revenue
- MYNZ $893,991.00
- SNOA $14,288,000.00
- Revenue This Year
- MYNZ $26.06
- SNOA $38.54
- Revenue Next Year
- MYNZ $4.97
- SNOA N/A
- P/E Ratio
- MYNZ N/A
- SNOA N/A
- Revenue Growth
- MYNZ N/A
- SNOA 12.20
- 52 Week Low
- MYNZ $1.34
- SNOA $1.75
- 52 Week High
- MYNZ $22.40
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- MYNZ 26.61
- SNOA 45.69
- Support Level
- MYNZ $1.35
- SNOA $2.81
- Resistance Level
- MYNZ $1.46
- SNOA $3.04
- Average True Range (ATR)
- MYNZ 0.12
- SNOA 0.14
- MACD
- MYNZ 0.02
- SNOA -0.01
- Stochastic Oscillator
- MYNZ 9.27
- SNOA 37.78
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.